Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Release Tacrolimus vs Standard Tacrolimus in Liver Transplantation
NCT00189826Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2004
- Primary completion
- Dec 2006
- Modality
- RNA-Targeting Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of tacrolimus in Liver transplant rejection (2 arms), sponsored by Astellas Pharma. Primary endpoint: Incidence of and time to biopsy-proven acute rejections at 12 months. Started Aug 2004; status: completed.
02
Drugs
tacrolimus
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT00189826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189826.